News Activity: Hertz Global Holdings, Inc., Cheetah Mobile (NYSE:CMCM), Catabasis Pharmaceuticals (NASDAQ:CATB), ImmunoCellular Therapeutics, (NYSEMKT:IMUC)

Rambus Inc. (NASDAQ:RMBS) shares fell -1.75% in last trading session and ended the day at $11.20. RMBS Gross Margin is 84.60% and its has a return on assets of 31.60%. Rambus Inc. (NASDAQ:RMBS) quarterly performance is 6.36%.

Rambus Inc. (NASDAQ:RMBS) reported Revenue for the fourth quarter of 2015 was $76.8 million, up 4% on a sequential basis from the third quarter of 2015 primarily due to higher contract and product revenue, offset by lower royalty revenue. As compared to the fourth quarter of 2014, revenue was up 7% primarily due to higher royalty revenue from SK hynix, IBM and the renewal of our patent license agreement with Toshiba in the fourth quarter of 2015 as well as higher contract revenue, offset by lower royalty revenue from Renesas and STMicroelectronics.

Hertz Global Holdings, Inc. (NYSE:HTZ) ended the last trading day at $9.33. Company weekly volatility is calculated as 8.23% and price to cash ratio as 8.15. Hertz Global Holdings, Inc. (NYSE:HTZ) showed a weekly performance of -4.01%.

Hertz Global Holdings, Inc. (NYSE:HTZ) announced that it Presented At The Deutsche Bank 2016 Global Auto Industry Conference on 13 January, 2016.

On 25 January, Cheetah Mobile Inc. (NYSE:CMCM) shares fell -2.48% and was closed at $14.14. Cheetah Mobile Inc. (NYSE:CMCM) year to date (YTD) performance is -11.74%.

Cheetah Mobile Inc. (NYSE:CMCM) announced that Moxiu Technology (Beijing) Co., Ltd. (“Moxiu”), a subsidiary of the Company, filed an application for the quotation of its shares on the National Equities Exchange and Quotations System (the “NEEQ”) in China on January 22, 2016. The NEEQ is commonly known as the New Third Board of the PRC, and is a unified national system that typically provides a trading platform for off market transfer of non-listed public shares by subscribing members of the NEEQ.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) shares advanced 14.46% in last trading session and ended the day at $6.65. CATB has a return on assets of -58.30%. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) quarterly performance is -5.27%.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), announced positive top-line results from Part A of the MoveDMD trial, a Phase 1 / 2 trial of CAT-1004 for the treatment of Duchenne muscular dystrophy (DMD or Duchenne). All three doses of CAT-1004 tested were generally well tolerated with no safety signals observed. The majority of adverse events were mild in nature, and the most common adverse events were gastrointestinal, primarily diarrhea.

ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) caters to the Healthcare space. Its weekly performance is -9.68%. On the last day of trading company shares ended up at $0.25. ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) distance from 50-day simple moving average (SMA50) is -33.51%.

Zacks Investment Research lowered shares of ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) from a hold rating to a sell rating in a research report sent to investors on Tuesday, Analyst Ratings Net reports.